At GenScript, we have the technical means & experience to synthesize large numbers of challenging neoantigen peptides and provide tailored optimization tools for your downstream applications.
Stages of Neoantigen Precision Immunotherapy
GenScript’s Neoantigen Peptide Synthesis Service can be used for everything from functional screening of neoantigen candidates for TCR therapy to clinical stage vaccine immunogenicity testing.
Tailored Synthesis For Any Application!
TCR-Antigen Affinity & Immunogenicity Screening
Personalized Cancer Vaccine (PCV)
-
PCV Efficacy Screening
Features of GenScript’s Service
Trustworthy Partner
in Neoantigen Synthesis-
High Success Rate for
Synthesis of Difficult Peptides 
Service Flexibility for
Personalized Therapy
"Reliable Reputation Amongst the Neoantigen Community"
"Screening hundreds of neoantigens in mice to validate the generalizability of SNP-7/8a was a tremendous undertaking that could not have been possible without the diligent efforts of GenScript's peptide chemists who were able to rapidly synthesize even the most challenging sequences at the high purity required."
―Geoffrey Lynn, Ph.D.
Avidea Technologies' CEO
Proven Reliability
Strong Application Expertise
- Produced 1000’s of peptides for TCR therapy screening for 3T Biosciences
- Synthesized Difficult peptides at varying amounts for Avidea’s novel SNAP PCV delivery system
- Generated highly immunogenic peptides for DNA-based PCV efficacy screening
Track Record of Success
- 15 years of peptide synthesis production with a 98% success rate
- Successful production of neoantigen peptides for the Top 50 immunotherapy companies and academic institutes
Continuous Communication
- Global presence allowing for 24/7 communication and technical support
- Project-specific managers and milestones
"Utilizing Reliable Synthesis Technologies & Tools for Superior Immunogenicity"
In 2019 GenScript manufactured 2500 neaontigen peptides with a 95% success rate using our tailored neoantigen peptide synthesis platform.
How Do We Do It?
Step One: Input EVERY one of your peptides through our proprietary NeoPre™ bioinformatics algorithm to determine synthesis difficulty
| Peptide # | Sequence | Length | Aggregation | Hydrophobicity | pI | Synthetic Difficulty |
|---|---|---|---|---|---|---|
| Example 1 | XXXXXXXX | 25 | 4.18 | -0.032 | 11.83 | Middle |
| Example 2 | XXXXXXXX | 25 | 31.63 | 0.49 | 10.06 | Hard |
| Example 3 | XXXXXXXX | 25 | -4.77 | -0.58 | 6.78 | Simple |
Step Two: Based on difficulty and project details we help you pick the right synthesis platform to maximize success
| Technology | Use Case |
|---|---|
| Microwave | Automated, High Yield, Fast TAT |
| Liquid-Phase | For modified peptides |
| Solid-Phase | Higher purity peptides |
Step Three: Once your peptides have been produced, GenScript offers library design tools to assist you optimize any neoantigen sequence
| Library | Use |
|---|---|
| Alanine Scanning | Determine the most important individual amino acids |
| Overlapping | Discover the perfect peptide length and sequence |
| T-Cell Truncation | Identify the best epitope for a specific activity |
"Reliable Peptide Yields In Your Timeline"
Neoantigens may require different yields, TAT, number, purity, ect, depending on their downstream application. To accommodate the needs of the neoantigen community, ALL of GenScript’s neoantigen peptide services are fully flexible and customizable.
Example Project 1: TCR Affinity and Immunogenicity Screening
GenScript offers a wide range of services to fit the needs of customers working on the beginning stages of T-cell therapy to clinical stage efficacy screening. Learn the various ways GenScript’s neoantigen peptide synthesis service can be customized to fit the peptide requirements of each phase, even including TCR affinity maturation and epitope identification! Read More »
Project Goal: Generate an Allogenic T-cell Therapy for Patient with Squamous Cell Carcinoma
Phase I: Phase I: After tumor biopsy and NGS, 300 different neoantigens were identified as possible candidates. These sequences were sent to GenScript to synthesize as a crude peptide library to be used for in-vitro functionality screening of TCR Binding Affinity and Efficacy.
| # Peptides Analyzed | # Peptides Synthesized | Avg Peptide length | Yield | Purity | TAT (B.D) | Quality Control | Synthesis Methods Used | Delivery |
|---|---|---|---|---|---|---|---|---|
| 300 | 290 | 30 AA | 2 mg/peptide | 70% | 20 | RP-HPLC LC-MS |
Simple: 68% of Peptides Synthesized Using Microwave Technology Difficult: 22% of Peptides Synthesized Using LP/SP Manual technology |
Lyophilized Peptides in Individual Aliquot Tubes |
Phase II: In-vitro functionality screening identified a top candidate, however, in order to increase the binding affinity and efficacy of the TCR, researchers decided to design and generate an overlapping library to map the specific interaction between neoantigen epitope and TCR.
| Library Type | Length | Offset | Overlap | # of Peptides | Purity | Yield | Delivery Format |
|---|---|---|---|---|---|---|---|
| Overlapping | 11 AA | 3 AA | 6 AA | 100 | 80% | 0.5 mg/peptide | Pooling all quantity of partial peptides (20 peptides/pool) |
Phase III: Once the specific epitope was identified, researchers designed and generated an alanine scanning library to determine which amino acids were most important for therapeutic efficacy, prior to affinity maturation of the TCR.
| Library Type | Length | Purity | Yield | Delivery Format |
|---|---|---|---|---|
| Alanine Scanning | 11 AA | 98% | 4 mg/peptide | Lyophilized Peptides in Individual Aliquot Tubes (1 mg/tube) |
Example Project 2: PCV Development
When generating a PCV, researchers require an array of peptide services due the specific needs of in vitro functionality screening, pre-clinical safety basement in laboratory models, and clinical efficacy analysis. Learn how GenScript’s neoantigen peptide synthesis service has flexible services which allow for reliable peptides for any phase of PCV development. Read More »
Project Goal: Generate a Personalized Cancer Vaccine for a patient with Glioblastoma
Phase I: After tumor biopsy and NGS, 150 different neoantigens were identified as possible candidates. These sequences were sent to GenScript to synthesize as a purified peptide library to be used for in-vitro functionality screening.
| # Peptides Analyzed | # Peptides Synthesized | Avg Peptide length | Yield | Purity | TAT (B.D) | Quality Control | Synthesis Methods Used | Delivery |
|---|---|---|---|---|---|---|---|---|
| 150 | 145 | 28 AA | 2 mg/peptide | 75% | 20 | RP-HPLC LC-MS Solubility Testing |
Simple: 60% of Peptides Synthesized Using Microwave Technology Difficult: 40% of Peptides Synthesized Using LP/SP Manual technology |
Lyophilized Peptides in Individual Aliquot Tubes (1 mg/vial) |
Phase II: In-vitro functionality screening identified 20 peptides for pre-clinical PCV development for non-human primate.
| # Peptides Analyzed | # Peptides Synthesized | Avg Peptide length | Yield | Purity | TAT (B.D) | Quality Control | Synthesis Methods Used | Delivery |
|---|---|---|---|---|---|---|---|---|
| 20 | 19 | 35 AA | 500 mg/peptide | 98% | 30 | RP-HPLC LC-MS Solubility Testing |
Simple: 30% of Peptides Synthesized Using Microwave Technology Difficult: 70% of Peptides Synthesized Using LP/SP Manual technology |
Lyophilized Peptides in Individual Aliquot Tube |
Phase III: After the vaccine was deemed “safe” through pre-clinical testing; the vaccine was used in a human patient. After inoculation, researchers required “vaccine” and “non-vaccine control” neoantigen peptides for clinical in-vitro efficacy screening of patient derived PBMC’s.
| # Peptides Analyzed | # Peptides Synthesized | Avg Peptide length | Yield | Purity | TAT (B.D) | Quality Control | Synthesis Methods Used | Delivery |
|---|---|---|---|---|---|---|---|---|
| 25 | 25 | 34 AA | 14 mg/peptide | 70% | 20 | RP-HPLC LC-MS |
Simple: 35% of Peptides Synthesized Using Microwave Technology Difficult: 65% of Peptides Synthesized Using LP/SP Manual technology |
Lyophilized Peptides in Individual Aliquot Tube (2 mg/vial) |
Check Out GenScript’s Neoantigen Peptide Resources
- Case Study: Using GenScript’s NeoPre bioinformatics algorithm for difficult neoantigen peptide synthesis New
- Case Study: Using GenScript’s NeoPre bioinformatics algorithm for difficult neoantigen peptide synthesis New
- Case Study: Pairing of Neoantigen-Reactive T-Cell Receptors Validated Against Mutated Peptides
- Application Note: Identifying COVID-19 Vaccine Epitopes Using Peptide Based T cell Activation Assays New
- Application Note: Identifying COVID-19 Vaccine Epitopes Using Peptide Based T cell Activation Assays New
- Nature Interview with 3T Biosciences: Using Neoantigen Peptides for Personalized T cell therapy New
- Nature Interview with 3T Biosciences: Using Neoantigen Peptides for Personalized T cell therapy New
- Interviews: Neoantigen-based precision therapeutics New
- Interviews: Neoantigen-based precision therapeutics New
- Editorials: Neoantigens: presenting new vaccine opportunities in immuno-oncology New
- Editorials: Neoantigens: presenting new vaccine opportunities in immuno-oncology New
- Expert View: GenScript’s unique four-tier platform forsuccessful synthesis of challenging neoantigen peptides for precision medicine
- Expert View: GenScript’s unique four-tier platform forsuccessful synthesis of challenging neoantigen peptides for precision medicine
- Interview: How GenScript’s NeoPre™ bioinformatics tool is changing the field of neoantigen peptide production for Immuno-oncology therapeutics
- Interview: How GenScript’s NeoPre™ bioinformatics tool is changing the field of neoantigen peptide production for Immuno-oncology therapeutics
- Editorials: Neoantigen Peptides in Precision Medicine
- Editorials: Neoantigen Peptides in Precision Medicine
- Podcast Review: Personalized cancer vaccine prospects improve with self-assembling nanoparticles
- Podcast Review: Personalized cancer vaccine prospects improve with self-assembling nanoparticles
